Paul Tesser, MD
Ophthalmology · Chesterfield, MONPI 1215945720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,050 of the $29,258 with a category attached, or 65.1%. 20 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 44.3% of the total. Reporting peaked in 2019 at $18,447 and has fallen 92.7% since, to $1,350 in 2025. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $91.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$13K
- AbbVie$10K
- Alcon$2K
- Lombart Brothers, Inc.$2K
- Bausch & Lomb Americas Inc.$362
- Aerie Pharmaceuticals, Inc.$346
- plus $1K from 14 others
What the payments were for
- Consulting fees$9753%
- Speaking & faculty fees$19,05065%
- Travel & lodging$8583%
- Food & beverage$8,33028%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 58 | $12,974 |
| AbbVie(2 entities) | 146 | $10,131 |
| Alcon | 51 | $2,215 |
| Lombart Brothers, Inc. | 1 | $2,000 |
| Bausch & Lomb Americas Inc. | 20 | $362 |
| Aerie Pharmaceuticals, Inc. | 10 | $346 |
| Carl Zeiss Meditec USA, Inc. | 2 | $297 |
| Glaukos Corporation | 6 | $278 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $235 |
| Thea Pharma Inc. | 6 | $121 |
| Amgen | 1 | $90 |
| Kala Pharmaceuticals, Inc. | 3 | $53 |
| Ivantis, Inc | 3 | $52 |
| Dompe US, Inc. | 1 | $24 |
| NEW World Medical,inc. | 2 | $16 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Lumibird Medical Inc. | 1 | $14 |
| Sight Sciences, Inc. | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $12 |
| Biotissue Holdings Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$11,996
- LUMIGAN$5,800
- OPD-III$2,000
- COMBIGAN$1,800
- DURYSTA$1,120
- XEN$365
- LenSx$345
- Clareon$292
- ARGOS$262
- IOLMaster 700$259
- Rocklatan$165
- Rhopressa$165
- iDose$150
- Unity$149
- ORA System VerifEye$145
- Tecnis IOL$135
- XEN GLAUCOMA TREATMENT SYSTEM$123
- Clareon PanOptix Pro$123
- NGENUITY$109
How this compares
$29,258 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 344 | $133,971 |
| CombiganBrimonidine Tartrate/Timolol | 202 | $69,531 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 372 | $64,499 |
| VyzultaLatanoprostene Bunod | 121 | $48,744 |
| ProlensaBromfenac Sodium | 58 | $25,291 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 96 | $23,344 |
| Latanoprost | 1,903 | $18,116 |
| Brinzolamide | 86 | $13,442 |
| Travoprost | 58 | $10,919 |
| Timolol Maleate | 1,020 | $9,464 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 462 | $7,057 |
| Prednisolone Acetate | 183 | $6,723 |
| Bromfenac Sodium | 21 | $6,297 |
| Alphagan PBrimonidine Tartrate | 16 | $5,875 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 19 | $3,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $10,131 | $209,377562 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $362 | $48,744121 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $12,974 | $28,39282 claims |
| AlconSimbrinza | $2,215 | $23,34496 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Chesterfield
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Mujtaba QaziChesterfield$15K
- Ibrahim Sayed-AhmedChesterfield$9K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.